Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

Canadian Cancer Trials Group MEC.4 (Alliance A091201) - A Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide / Dacarbazine in Ocular Melanoma - was centrally activated on July 9, 2015.

The primary objective of the trial is to compare the progression-free survival rate at 4 months of patients with ocular melanoma treated with cabozantinib or temozolomide (or dacarbazine).

Secondary objectives include to:
  • Estimate the distribution of progression-free survival times;
  • Estimate the distribution of overall survival times;
  • Estimate the confirmed response rate as determined by the RECIST criteria;
  • Assess the safety of these agents by examining the toxicity profile; and,
  • Correlate the response of MET molecular status.

Any centres interested in participating on this trial should contact Dora Nomikos at 613-533-6430 or